GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » ROE % Adjusted to Book Value

Median Technologies (XPAR:ALMDT) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Median Technologies ROE % Adjusted to Book Value?

Median Technologies's ROE % for the quarter that ended in Dec. 2023 was 0.00%. Median Technologies's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Median Technologies's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.


Median Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Median Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Median Technologies ROE % Adjusted to Book Value Chart

Median Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.28 - - - -

Median Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.81 -1.70 - - -

Competitive Comparison of Median Technologies's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Median Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Median Technologies's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Median Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Median Technologies's ROE % Adjusted to Book Value falls into.



Median Technologies ROE % Adjusted to Book Value Calculation

Median Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Median Technologies's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Median Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Median Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Median Technologies Business Description

Traded in Other Exchanges
Address
1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and iBiopsy for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Its geographical segments are France, the USA/Canada, the United Kingdom, China, and Other countries.

Median Technologies Headlines

No Headlines